Retinitis Pigmentosa Treatment & Management Market - Global Industry Trend Analysis 2012 to 2017 and Forecast 2017 - 2025


#11970

Persistence Market Research

$ 4900

The demand within the global retinitis pigmentosa treatment and management market has been rising on account of advancements in the field of ophthalmology. The field of ophthalmology has undergone rapid advancements over the past decade, and several improved treatment mechanisms have been developed. Hence, the treatment of retinitis pigmentosa has also become more efficient and swift. 

Retinitis pigmentosa is a type of genetic disorder characterised by the loss of cells inside the retina. Since the retina is responsible for sensing light in the eyes, retinitis pigmentosa results in progressive loss of vision. Hence, it is extremely important to treat, manage, and control retinitis pigmentosa in individuals of all age groups. It is expected that the global retinitis pigmentosa treatment and management market would earn humongous revenues in the years to follow. 

The global retinitis pigmentosa treatment and management market has been tracing an upward graph of growth. The impetus given on treating rare ophthalmological disorders in humans has played a major role in the growth of the global retinitis pigmentosa treatment and management market. Furthermore, the efforts of the medical fraternity to prevent loss of night vision in humans have also generated commendable demand within the global retinitis pigmentosa treatment and management market. 

On the basis of geography, the global retinitis pigmentosa treatment and management market can be segmented into North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. The retinitis pigmentosa treatment and management market in North America is expanding alongside advancements in the field of ophthalmology in the US.

Retinitis pigmentosa is a group of inherited retinal diseases that affects about 100,000 Americans and 1.5 million people worldwide. It is part of a group of rare genetic disorders that cause slow but progressive degeneration of photoreceptor cells in the retina. RP symptoms typically begin in childhood with decreased night vision, followed by loss of peripheral vision, and can eventually lead to complete loss of vision. It causes the progressive deterioration of specialized, light-absorbing cells in the retina, the paper-thin tissue that lines the back of the eye like film in a camera.

Currently, there is no known effective treatment for retinitis pigmentosa (RP). However, since 1992, doctors in Cuba have offered a treatment for RP at an initial cost of just over $10 000 CDN. The Cuban treatment comprises eye surgery, ozone therapy, electric stimulation, and drugs. However, no independent, peer-reviewed studies have been conducted to date that demonstrate the Cuban treatment improves or stabilizes retinal function. Later, the Canadian Ophthalmological Society does not recommend the Cuban treatment for patients with RP due to the absence of objective, peer-reviewed evidence to support its efficacy, safety, and the fact that in some cases the treatment appears to have worsened patients’ RP symptoms.

According to researchers, the estimated population to be treated is 30,000 - 50,000, suffering by retinitis pigmentosa. Whereas, the projected price per dose could be $100,000. It is expected that, the annual yield by the treatment is $3-5 billion.

Since there are no proper treatment for retinitis pigmentosa, most people afflicted with the genetic disorder progress to the advanced stage of retinitis pigmentosa because of the dearth of proper cure. However, it has opened up a window of opportunity for new therapies and treatments. Companies are now focusing towards retinal prosthesis devices for restoring the lost vision. Second Sight Medical Products, Inc., for example, offers FDA approved Argus II retinal prosthesis system meant for patients with advanced retinitis pigmentosa. This device does the function of degenerated retinal cells and enhances the patient’s ability to see images and movement.

Also, a new approach known as optogenetics, which involves applying gene therapy for restoring vision, is currently being researched upon by companies operating in the ophthalmology market. It helps to power cells, especially ganglion cells, to respond to light after the degeneration of rod cells and cone cells. Further, the orphan drug designation given by the FDA and European Commission to ReN003 by ReNeuron in the U.S. and Europe in 2013 is another positive development in the market. ReN003 is a retinal stem cell therapy candidate.

The global market for retinitis pigmentosa treatment & management market can be segmented on basis of treatment and geography:

  • Segmentation by Treatment
    • Vitamin A
    • Docosahexaenoic acid (DHA)
    • Calcium channel blockers
    • Gene therapy
    • Retinal eye prosthetics

On the other hand, there are presence of some traditional/theoretical uses with minimum evidence, such as, bilberry, magnet therapy, ozone therapy and vitamin E. 

On the basis of regional presence, global retinitis pigmentosa treatment & management market can be segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Europe collectively expected to dominate the global retinitis pigmentosa treatment & management market due to upcoming approvals, more number of research and awareness. However, APAC to grow lately in this market due to large patient pool hence large demand.

There are some companies which are in to development and commercialization of products in this field, such as ReNeuron Group plc, Amarantus BioScience Holdings, Inc., Ocugen, Inc., ReGenX Biosciences, LLC, Sucampo Pharmaceuticals, Orphagen Pharmaceuticals, Inc., Inc., and Okuvision GmbH, Second Sight Medical Products, Inc.

The report covers exhaustive analysis on:

  • Retinitis Pigmentosa Treatment & Management Market Segments
  • Retinitis Pigmentosa Treatment & Management Market Dynamics
  • Retinitis Pigmentosa Treatment & Management Market Size & Forecast 2016 To 2024
  • Retinitis Pigmentosa Treatment & Management Current Trends/Issues/Challenges
  • Competition & Companies Involved
  • Retinitis Pigmentosa Treatment & Management Market Drivers and Restraints

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • The Middle East & Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

  • Tailwinds and headwinds molding the market’s trajectory
  • Market segments based on products, technology, and applications
  • Prospects of each segment
  • Overall current and possible future size of the market
  • Growth pace of the market
  • Competitive landscape and key players’ strategies

The main aim of the report is to:

  • Enable key stakeholder’s in the market bet right on it
  • Understand the opportunities and pitfalls awaiting them
  • Assess the overall growth scope in the near term
  • Strategize effectively with respect to production and distribution

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.